567,704 Recursion Pharmaceuticals, Inc. $RXRX Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. decreased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 10.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,943,983 shares of the company’s stock after selling 567,704 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Recursion Pharmaceuticals were worth $20,419,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. MCF Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the 2nd quarter worth $27,000. Park Avenue Securities LLC purchased a new position in Recursion Pharmaceuticals in the third quarter valued at about $47,000. Fund Advisors of America Inc FL purchased a new position in Recursion Pharmaceuticals in the second quarter valued at about $45,000. Sequoia Financial Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares in the last quarter. Finally, QRG Capital Management Inc. acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth about $47,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the transaction, the director owned 6,108,287 shares in the company, valued at $29,564,109.08. The trade was a 0.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the completion of the transaction, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. The trade was a 13.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 167,408 shares of company stock worth $701,276 in the last quarter. 6.65% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals News Summary

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion reported Q3 revenue of $18.55 million, above analysts’ $14.81 million estimate, while its loss of $0.22 per share matched expectations. The company also highlighted promising clinical data for REC-4881 and REC-1245 and said disciplined spending extends its cash runway into 2029. RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
• Positive Sentiment: Fred Hassan is taking the chairmanship following a Phase 2 win, adding an experienced leader as the company advances its drug pipeline. Recursion Pharmaceuticals Puts Fred Hassan In The Chair After Phase 2 Win
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating a cautious stance rather than a new positive or negative call. Bank of America Securities Remains a Hold on Recursion Pharmaceuticals
• Negative Sentiment: The anticipated FDA discussion about REC-4881 was inconclusive, with further clarity pushed to year-end. The delay leaves uncertainty around a potential development catalyst. RXRX Earnings: Revenue beats expectations, but FDA discussion on REC-4881 remains inconclusive
• Negative Sentiment: Director Blake Borgeson sold 40,000 shares for $155,200. The sale was made under a pre-arranged Rule 10b5-1 plan, and he continues to hold more than 6 million shares, which may temper the signal. Recursion Pharmaceuticals Director Sells $155,200 in Stock

Recursion Pharmaceuticals Trading Down 9.8%

NASDAQ RXRX opened at $3.50 on Friday. The stock has a market cap of $1.87 billion, a P/E ratio of -3.89 and a beta of 1.15. The company’s fifty day simple moving average is $3.77 and its 200-day simple moving average is $3.52. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $5.24.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.22). The business had revenue of $18.55 million during the quarter, compared to analyst estimates of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same period last year, the business earned ($0.36) EPS. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a report on Friday, October 16th. Finally, Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $8.18.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.